Dr. Michot on the Examination of CC-99282 in Relapsed/Refractory NHL


Jean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.

Jean-Marie Michot, MD, medical oncologist, the Department of Hematology and Innovative Drugs, the Institut de Cancérologie Gustave Roussy, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma (NHL).

Because there are few options for treatment in patients with relapsed/refractory NHL, investigations are ongoing to find new chemotherapy-free therapy options, Michot says. This has led to the examination of CC-99282 as a chemotherapy-free treatment, and the agent is based on protein degraders acting as molecular glue degraders, Michot explains.

Preclinical models demonstrated that when compared with other immunomodulatory agents, CC-99282 produced an increased apoptotic and antiproliferative activity, Michot adds. These data led to the rationale of utilizing this agent in a phase 1 trial (NCT03930953), where findings from the dose escalation portion of the trial showed that CC-99282 demonstrated encouraging responses and a favorable safety profile, with low rates of serious febrile neutropenia, Michot concludes.

Related Videos
Phillip J. Koo, MD
Daniel Petrylak, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Debra L. Richardson, MD, FACS, FACOG
Michael J. Overman, MD
Bernard H. Bochner, MD, FACS